Identification of novel myelodysplastic syndromes prognostic subgroups by integration of inflammation, cell-type composition, and immune signatures in the bone marrow
Preprint
Abstract
Mutational profiles of Myelodysplastic syndromes (MDS) have established that a relatively small number of genetic aberrations, including SF3B1 and SRSF2 spliceosome mutations, lead to specific phenotypes and prognostic subgrouping. We performed a Multi-Omics Factor Analysis (MOFA) on two published MDS cohorts of bone marrow mononuclear cells (BMMNCs) and CD34+ cells with three data modalities (clinical, genotype, and transcriptomics). Seven different views, including immune profile, inflammation/aging, Retrotransposon (RTE) expression, and cell-type composition, were derived from these modalities to identify the latent factors with significant impact on MDS prognosis. SF3B1 was the only mutation among 13 mutations in the BMMNC cohort, indicating a significant association with high inflammation. This trend was also observed to a lesser extent in the CD34+ cohort. Interestingly, the MOFA factor representing the inflammation shows a good prognosis for MDS patients with high inflammation. In contrast, SRSF2 mutant cases show a granulocyte-monocyte progenitor (GMP) pattern and high levels of senescence, immunosenescence, and malignant myeloid cells, consistent with their poor prognosis. Furthermore, MOFA identified RTE expression as a risk factor for MDS. This work elucidates the efficacy of our integrative approach to assess the MDS risk that goes beyond all the scoring systems described thus far for MDS.Keywords
All Related Versions
- Published version: eLife, 13.
This publication has 44 references indexed in Scilit:
- MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cellsJournal of Leukocyte Biology, 2020
- Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and ImmunityCell, 2019
- Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysisCritical Reviews in Oncology/Hematology, 2019
- Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene MutationsCancer Cell, 2018
- Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium AnalysisClinical Lymphoma Myeloma and Leukemia, 2018
- Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromesTumor Biology, 2015
- Landscape of genetic lesions in 944 patients with myelodysplastic syndromesLeukemia, 2013
- Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting CellsImmunity, 2013
- Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cellsLeukemia, 2010
- Tumor antigen-specific T helper cells in cancer immunity and immunotherapyCancer Immunology, Immunotherapy, 2005